

MITRAPHANOUS et al
Serial No. Unknown

retroviral vector according to claim 10, for use in medicine] claim 1 and a pharmaceutically acceptable diluent.

13. (Amended) [Use of] A method of delivering a NOI to a target site comprising contacting a retroviral delivery system according to [any one of claims 1 to 8, or a viral particle according to claim 9, or a retroviral vector according to claim 10, in the manufacture of a pharmaceutical composition to deliver a NOI to a target site in need of same] claim 1 with said site.

14. (Amended) A method comprising contacting a cell with a retroviral delivery system according to [any one of claims 1 to 8, or a viral particle according to claim 9, or a retroviral vector according to claim 10] claim 1 or a viral particle obtainable therefrom.

Claim 20, line 2, delete "or claim 17".

REMARKS

The above amendments are made to place the claims in a more traditional format.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: B. J. Sadoff

B. J. Sadoff

Reg. No. 36,663

BJS:Imy

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100